YERVOY 5 mg/ml concentrate for solution for infusion, RP2, OPDIVO 10 mg/mL concentrate for solution for infusion., RP2 clinical trials

A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma

This study looks at new ways to treat a type of skin cancer in the eye that has spread (metastatic uveal melanoma). It compares two drug combinations, RP2 with Nivolumab, against Ipilimumab with Nivolumab, to see which is safer and more effective.